Comprehensive Preclinical Package for Anti-Obesity Drug Development
We provide an integrated preclinical platform designed to accelerate drug discovery and support rigorous preclinical drug testing, enabling the development of next-generation anti-obesity therapies through robust disease models and comprehensive assessments of efficacy, safety, and muscle function.
Key Challenges in Anti-Obesity Drug Development
Despite recent advances in incretin-based therapies, anti-obesity drug development remains challenging due to the complex and multifactorial nature of obesity. Effective therapies must achieve sustained body weight reduction while minimizing loss of lean mass, balance metabolic efficacy with gastrointestinal tolerability, and engage central mechanisms that regulate appetite and energy homeostasis. In parallel, early identification of muscle-related safety liabilities has become increasingly critical, as preservation of muscle mass and function is closely linked to long-term metabolic health. To successfully translate preclinical findings into clinically meaningful outcomes, a robust and translational preclinical evaluation strategy is essential to de-risk development and support rational candidate selection.
{{ item.title }}
{{static_tabs[0].title}}
Why Our Integrated Preclinical Platform
Accelerate your metabolic disease research with our end-to-end preclinical solutions, designed to de-risk and expedite your drug discovery pipeline.
Cyagen Mouse Atlas
Multidimensional Efficacy Assessment
Early Safety & Tolerability Screening
Muscle Mass & Function Preservation Evaluation
Translational Decision Support
Relevant Model
| Catalog Number | Name | Base Strain | Research Application | Action |
|---|---|---|---|---|
| {{ value.product_num || "--" }} | {{ value.product_name || "--" }} | {{ value.product_strain || "--" }} |
|
+
|
{{static_tabs[1].title}}
Case Studies
Case 1 - Validation of Therapeutic Efficacy of GLP-1/GIP/GCGR Receptor Agonists in the DIO
Mouse
Model
{{ item.label }}
{{v2.label}}
{{v2.title}}
{{item.title}}
Case2-Validation of Therapeutic Efficacy of GLP-1/GIP/GCGR and Amylin Receptor Agonists in
the DIO Rat Model
{{ item.label }}
{{v2.label}}
{{v2.title}}
{{item.title}}
{{static_tabs[2].title}}
Gastrointestinal Side Effect Screening
Gastrointestinal tolerability is a critical determinant of clinical success for
anti-obesity drugs. We provide early-stage screening tools in mice and rats to identify
potential liabilities:
| Assay | Description | Species |
|---|---|---|
| Acute food intake assay | Single-dose administration with food intake measured over 24 hours for rapid efficacy screening. | Rat/mouse |
| Conditioned Taste Aversion (CTA) test | Early evaluation of drug-induced malaise and gastrointestinal intolerance for early candidate de-selection. | Rat/mouse |
| Gastric emptying assay | Blood-based measurements to evaluate gastric motility and support early-stage candidate selection. | Rat/mouse |
Muscle Preservation & Sarcopenia Assessment
Dexamethasone (Dex)-induced Sarcopenia Mouse Model
Evaluations via grip strength testing, body composition analysis, and histopathology revealed
that Dex induction significantly reduced muscle explosive power and whole-body muscle mass,
while markedly decreasing the cross-sectional area (CSA) of muscle fibers. These findings
indicate significant impairment in both muscle strength and structural integrity. Characterized
by stability, controllability, and high reproducibility, this model serves as a robust
preclinical tool for evaluating muscle-protective and anti-atrophy agents, making it suitable
for both efficacy screening and mechanistic studies.
Figure 1. Schematic illustration of the dexamethasone-induced sarcopenia mouse model.
Figure 2. A significant reduction in grip strength was observed in the
Dexa-induced model
group after 14 days of treatment.
Establishment of the sarcopenia model via chronic dexamethasone (Dexa) administration.
Data
are presented as Mean±SEM, N=6 mice per group. Statistical analysis was performed using
T-test, *p<0.05, **p<0.01 vs. G1-Vehicle, ##p<0.01 vs. G2- Dexa Baseline.
Figure 3. Body composition analysis showing a marked reduction in whole-body
muscle mass
and muscle proportion after 14 days of Dexatreatment.
Establishment of the sarcopenia model via chronic dexamethasone (Dexa)
administration.
Data are presented as Mean±SEM, N=6 mice per group. Statistical analysis was performed
using T-test, *p<0.05, **p<0.01 vs. G1-Vehicle, ##p<0.01 vs. G2- Dexa Baseline.
Figure 4. Muscle weight analysis demonstrating significant reductions
in GAS, TA, and SOL muscle mass after 14 days of Dexa treatment.
Establishment of the sarcopenia model via chronic dexamethasone
(Dexa)
administration. Data are presented as Mean±SEM, N=6 mice per group. Statistical
analysis was performed using T-test, *p<0.05, **p<0.01 vs. G1-Vehicle, ##p<0.01 vs.
G2- Dexa Baseline.
Figure 5. The dexamethasone-induced model group showed decreases in
muscle fiber cross-sectional area in the gastrocnemius and tibialis anterior
muscles.
Establishment of the sarcopenia model via chronic
dexamethasone
(Dexa)
administration. Data are presented as Mean±SEM, N=6 mice per group. Statistical
analysis was performed using T-test, *p<0.05, **p<0.01 vs. G1-Vehicle, ##p<0.01
vs. G2- Dexa Baseline.
Figure 6. Dex-induced sarcopenia led to a significant impairment
in exercise endurance in mice, as assessed by treadmill testing, with
marked reductions in running time and total running distance.
Establishment of the sarcopenia model via chronic
dexamethasone (Dexa) administration. Data are presented as Mean±SEM, N=6
mice per group. Statistical analysis was performed using T-test, *p<0.05,
**p<0.01 vs. G1-Vehicle, ##p<0.01 vs. G2- Dexa Baseline.
Why Partner with Cyagen?
In-stock validated obesity models
We provide ready-to-use diet-induced obesity (DIO) mouse and rat models to bypass prolonged induction phases and accelerate your research timelines.
Advanced metabolic phenotyping
We offer comprehensive body composition and metabolic monitoring to accurately evaluate fat reduction while assessing muscle mass preservation.
Experienced pharmacology team
Leverage our PhD-level experts to bridge the gap between preclinical data and clinical milestones.
Related Resources
Events & Webinars
Beyond the mouse: Accelerating Drug Discovery for Obesity & T2D with HUGO-GT™
View Details
Promotional Campaign
Flash Drop — Ready-to-Ship KO/cKO Mice
View Details
Blogs & Insights
In Vivo CAR-T Enters Clinical Validation: How It Works and What Comes Next
View Details
Resource Valut
HUGO-GT™ Models：Efficacy Data & Core Advantages for Small Nucleic Acid Drug Therapeutics
View Details
Request a Preclinical CRO Services Consultation
Partner with Cyagen to advance your preclinical studies. Share your project goals with us and receive customized support.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
